Glenmark Generics Gets U.S. FDA Approval For Two More Drugs
This article was originally published in PharmAsia News
Executive Summary
India's Glenmark Generics received approval from U.S. FDA for its generic versions of Schering's Elocon (mometasone) and Bristol Myers Squibb's Metaglip (metformin hydrochloride). The approvals increase the portfolio of the Glenmark Pharmaceutical subsidiary to 32 generics on the U.S. market. CGL has another 35 generic applications in the mill at U.S. FDA. (Click here for more